Previous 10 | Next 10 |
Excitement over December 2023 launch of ZURZUVAE™ (zuranolone), the first and only oral treatment indicated for adults with postpartum depression (PPD) Continued progress on clinical pipeline, with topline data expected from multiple ongoing Phase 2 trials across 2024 ...
Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the retirement of Kevin Starr from the company’s board of directors. Geno Germano has assumed the role of Chair of the Board of Directors. Mr....
Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the 42 nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 4:30 p.m. PT in San Francisco, CA. ...
2023-12-27 12:29:36 ET More on AbbVie, Johnson & Johnson, etc. Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase Eli Lilly: Consider Cutting Before The Southbound Train Leaves (Rating Downgrade) AbbVie Vs. GSK: Dual Dominance In Pharma ...
2023-12-25 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-12-14 13:38:30 ET More on Sage Therapeutics Sage Therapeutics: Postpartum Pioneer Or Fiscal Folly, Zurzuvae Dilemma SAGE Therapeutics, Inc. (SAGE) Q3 2023 Earnings Call Transcript Sage Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation Sag...
ZURZUVAE, the first and only oral, once-daily, 14-day treatment course, has shown to provide rapid improvements in depressive symptoms at Day 15 and as early as Day 3 for women with PPD Patient support program, ZURZUVAE For You, and financial assistance available to eligible women with PPD pr...
2023-11-29 15:00:01 ET Summary Biogen's latest Alzheimer's drug, Aduhelm, faced challenges after FDA approval, leading to concerns about efficacy and high costs. Biogen and Eisai's latest FDA-approved lecanemab faces similar risks; as a result, shares are down over 20% year-over-y...
2023-11-20 00:24:09 ET Summary Biotech stocks have been heavily impacted by rising interest rates and the disruption caused by FTC-challenging acquisitions of biotechs. The equal-weight biotech ETF (XBI) has shown signs of a rebound after a prolonged downtrend, potentially due to ...
2023-11-10 06:57:27 ET Summary Sage Therapeutics' flagship product, Zurzuvae for PPD, faces market adoption challenges due to its controlled substance status. Increasing R&D expenses and a high burn rate raise concerns about Sage's long-term financial sustainability. Sage'...
News, Short Squeeze, Breakout and More Instantly...
Sage Therapeutics Inc. Company Name:
SAGE Stock Symbol:
NASDAQ Market:
Sage Therapeutics Inc. Website:
- SAGE-324 (BIIB124) did not demonstrate a statistically significant dose-response relationship on the primary endpoint in participants with essential tremor - No statistically significant differences were demonstrated between any dose of SAGE-324 and placebo in the change from baseline...
Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced that it will host a live webcast on Wednesday, July 31, 2024 at 4:30 p.m. ET to review second quarter 2024 financial results and discuss recent business ...
2024-06-20 13:15:04 ET Scotiabank analyst issues UNDERPERFORM recommendation for SAGE on June 20, 2024 10:00AM ET. The previous analyst recommendation was Underperform. SAGE was trading at $10.525 at issue of the analyst recommendation. The overall analyst consensus : HO...